The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. BeOne Medicines Ltd.'s recent Forms 8-K announced quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in-licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
Form 144 filing reports ADS dispositions by an affiliate of the issuer. The notice lists ADS as the security type with dates in June 2026 and specific recent dispositions: 1,949 ADS for $501,354.72 on 06/11/2026 and 4,940 ADS for $1,336,547.63 on 06/08/2026. The filing also references a restricted stock vesting under a registered plan dated 06/15/2026.
BeOne Medicines Ltd. principal accounting officer Titus B. Ball reported a mix of compensation-related share activity and tax-driven sales. On June 11, 2026, he had 169 American Depositary Shares sold in open-market transactions, with prices around $256–$258 per ADS. A footnote explains these sales were executed under a mandatory tax withholding provision tied to the vesting of an earlier restricted share unit award, rather than discretionary selling. The same day, he received a grant of 31,213 Ordinary Shares underlying restricted share units at no purchase price, bringing his direct holdings to 99,645 Ordinary Shares. These restricted share units vest in four equal annual installments starting on June 11, 2026, with potential accelerated vesting upon certain termination events. Each ADS represents 13 Ordinary Shares, connecting the ADS activity to the underlying ordinary share structure.
BeOne Medicines Ltd. executive Wang Lai reported equity compensation grants and a small tax‑related share sale. He received 118,625 Ordinary Shares as a restricted share unit award and 229,775 share options with a $20.81 exercise price, both vesting over four years, subject to continued service and potential accelerated vesting upon certain termination events.
A total of 756 American Depositary Shares, each representing 13 Ordinary Shares, were sold at a weighted average price of about $261.00 per ADS under a mandatory tax withholding provision tied to a prior restricted share unit vesting, rather than a discretionary open‑market sale. Following these transactions, he directly holds 1,710,085 Ordinary Shares and 229,775 options, while additional Ordinary and RMB Shares are held by entities such as Wang Holdings LLC and the RMB Shares Employee Participation Plan, over which he disclaims Section 16 beneficial ownership and generally lacks voting or dispositive power.
BeOne Medicines Ltd. Chief Financial Officer Aaron Rosenberg reported routine equity compensation activity and a small tax-related sale. He sold 631 American Depositary Shares in an open-market transaction at a weighted average price of $257.7441 per ADS, executed pursuant to a mandatory tax withholding provision tied to a previously granted restricted share unit award. Each ADS represents 13 Ordinary Shares.
Rosenberg also received 71,175 Ordinary Shares as a grant or award, bringing his direct Ordinary Share holdings to 397,891 shares. In addition, he was granted options over 137,865 Ordinary Shares with an exercise price of $20.81 per share, expiring on June 10, 2036. Both the new restricted share units and options vest over four years, with 25% vesting on the first anniversary of June 11, 2026 and the remainder vesting in equal installments thereafter, subject to continued service and potential accelerated vesting upon certain termination events.
BeOne Medicines President and COO Wu Xiaobin reported new equity awards and a small tax-related sale. He received 118,625 Ordinary Shares through a restricted share unit grant and 229,775 share options with a $20.81 exercise price, both as compensation.
He also sold 626 American Depositary Shares at a weighted average price of $261.2017 per ADS to satisfy mandatory tax withholding tied to earlier restricted share unit vesting. After these awards, he directly holds 1,308,161 Ordinary Shares and 229,775 share options, and indirectly 4,000 ADS held by his wife.
BeOne Medicines Ltd. senior vice president and general counsel Henry Lee Chan reported a mix of equity transactions. He sold 428 American Depositary Shares at $257.635 per ADS pursuant to a mandatory tax withholding provision tied to a previously granted restricted share unit award. Each ADS represents 13 Ordinary Shares.
He also acquired 45,071 Ordinary Shares underlying restricted share units that vest over four years starting on June 11, 2026, with 1/4 vesting on each anniversary, subject to continued service. In addition, he received a share option for 87,308 Ordinary Shares at an exercise price of $20.81 per share, expiring on June 10, 2036, vesting 25% on the first anniversary of June 11, 2026 and monthly thereafter. Following these transactions, he directly holds 346,554 Ordinary Shares and 87,308 options.
BeOne Medicines Ltd. Chief Executive Officer John Oyler reported a mix of equity awards and routine share sales related to tax withholding. He received 177,931 Ordinary Shares underlying restricted share units, scheduled to vest in four equal annual installments starting on June 11, 2026, with potential accelerated vesting upon a change of control or certain termination events.
Oyler also received a share option covering 344,669 Ordinary Shares at an exercise price of $20.8100 per share, vesting over four years on a similar schedule. The filing shows open‑market sales totaling 1,949 American Depositary Shares at weighted average prices around $256–$259; these were effected under a mandatory tax withholding provision tied to a previously granted restricted share unit award. Each American Depositary Share represents 13 Ordinary Shares. Several large blocks of Ordinary Shares are held indirectly through trusts, an LLC, and a Roth IRA account, and the filing states that Oyler disclaims beneficial ownership of multiple indirect holdings.
BeOne Medicines Ltd. director and scientific advisory board chair Xiaodong Wang reported new equity awards. He received 99,892 Ordinary Shares at a price of $0.00 per share, bringing his direct holdings to 4,682,493 Ordinary Shares after the award.
Wang was also granted a share option for 193,492 Ordinary Shares with an exercise price of $20.81 per share, expiring on June 10, 2036. The footnotes state that these option shares vest over four years, with 25% vesting on the first anniversary of June 11, 2026 and the remainder in 36 monthly installments, subject to continued service. Additional Ordinary Shares are held indirectly by a family trust, Wang Investment LLC, and Wang’s spouse, for which he disclaims beneficial ownership. Each American Depositary Share represents 13 Ordinary Shares.
BRANDICOURT OLIVIER reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Olivier Brandicourt received a grant of 18,980 Ordinary Shares in the form of restricted share units on June 11, 2026 at no cash cost, as director compensation. These restricted share units vest in full on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and potential accelerated vesting under the company’s Independent Non-Executive Director Compensation Policy. Following this award, Brandicourt directly holds 46,306 Ordinary Shares.
HOOPER ANTHONY C reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Anthony C. Hooper received an equity grant of 18,980 Ordinary Shares in the form of restricted share units at no cash cost on 2026-06-11. These restricted share units vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and any accelerated vesting provisions under the company’s Independent Non-Executive Director Compensation Policy. Following this grant, Hooper holds 83,720 Ordinary Shares directly.